Nanatinostat + Valganciclovir + Pembrolizumab
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nasopharyngeal Carcinoma
Conditions
Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma, EBV-Related Sarcoma
Trial Timeline
Oct 8, 2021 → Jan 10, 2025
NCT ID
NCT05166577About Nanatinostat + Valganciclovir + Pembrolizumab
Nanatinostat + Valganciclovir + Pembrolizumab is a phase 1 stage product being developed by Viracta Therapeutics for Nasopharyngeal Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05166577. Target conditions include Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma.
What happened to similar drugs?
0 of 13 similar drugs in Nasopharyngeal Carcinoma were approved
Approved (0) Terminated (0) Active (13)
🔄PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05166577 | Phase 1 | Terminated |
Competing Products
20 competing products in Nasopharyngeal Carcinoma